The aim of this study was to evaluate the efficacy of canagliflozin in reducing the required insulin dose and the risk of hypoglycaemia in type 2 diabetes (T2D). This study was conducted in patients with T2D treated with insulin. They were randomly assigned to the control (n = 17) and canagliflozin (n = 17, plus 100 mg/day canagliflozin) groups. In both groups, a defined insulin dose adjustment protocol was applied to achieve the same level of glycaemic control. The change from baseline in daily insulin dose was significantly smaller in the canagliflozin group (3.9 units/day) than in the control group (13.4 units/day; P = 0.040). Low blood glucose index and predicted % of blood glucose (BG) <70 mg/dL, which are hypoglycaemia-related variables, worsened significantly in the control group but both remained unchanged in the canagliflozin group. The standard deviation for night-time BG levels improved significantly only in the canagliflozin group. Supplementation of insulin therapy with 100 mg canagliflozin in patients with T2D reduced the required insulin dose and hypoglycaemic risk and flattened night-time glycaemic fluctuations while maintaining the same level of glycaemic control.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/dom.13770 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Association Between Four Non-Insulin-Based Insulin Resistance Indices and the Risk of Post-Stroke Depression.
Clin Interv Aging
January 2025
Department of Neurology, the Affiliated Huai'an Hospital of Xuzhou Medical University, Huai'an, Jiangsu, People's Republic of China.
Purpose: Research suggests that insulin resistance (IR) is associated with acute ischemic stroke (AIS) and depression. The use of insulin-based IR assessments is complicated. Therefore, we explored the relationship between four non-insulin-based IR indices and post-stroke depression (PSD).
View Article and Find Full Text PDFEfficacy, safety and treatment satisfaction of transition to a regimen of insulin degludec/aspart: A pilot study.
World J Diabetes
January 2025
Department of Endocrinology, Key Laboratory of Endocrinology of National Health Commission, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.
Background: There is a lack of clinical evidence on the efficacy and safety of transitioning from a thrice-daily pre-mixed insulin or basal-prandial regimen to insulin deglu-dec/aspart (IDegAsp) therapy, with insufficient data from the Chinese popu-lation.
Aim: To demonstrate the efficacy, safety, and treatment satisfaction associated with the transition to IDegAsp in type 2 diabetes mellitus (T2DM).
Methods: In this 12-week open-label, non-randomized, single-center, pilot study, patients with T2DM receiving thrice-daily insulin or intensive insulin treatment were transitioned to twice-daily injections of insulin IDegAsp.
Application of Dorzagliatin in peritoneal dialysis patients with type 2 diabetes mellitus: A case report.
World J Diabetes
January 2025
Department of Endocrinology, Beijing Haidian Hospital, Beijing 100080, China.
Background: Treating diabetes in dialysis patients remains a challenge, with many hypoglycemic drugs requiring dose adjustments or avoidance in these patients.
Case Summary: This report describes an 83-year-old female patient with a 30-year history of type 2 diabetes (T2DM) who had struggled to control her blood sugar for more than a year. She had a history of high blood pressure for 30 years, had undergone continuous ambulatory peritoneal dialysis for more than two years, was 163 cm tall, weighed 77 kg, and had a body mass index of 28.
Triglyceride glucose index-body mass index as a predictor of coronary artery disease severity in patients with H-type hypertension across different glucose metabolic states.
Diabetol Metab Syndr
January 2025
Department of Cardiology, Wuhan Third Hospital & Tongren Hospital of Wuhan University, Wuhan, 430074, Hubei, China.
Background: The triglyceride glucose-body mass index (TyG-BMI) is considered to be a reliable surrogate marker of insulin resistance (IR). However, limited evidence exists regarding its association with the severity of coronary artery disease (CAD), particularly in hypertensive patients with different glucose metabolic states, including those with H-type hypertension. This study aimed to investigate the relationship between TyG-BMI and CAD severity across different glucose metabolism conditions.
View Article and Find Full Text PDFTirzepatide and Cancer Risk in Individuals with and without Diabetes: A Systematic Review and Meta-Analysis.
Endocrinol Metab (Seoul)
January 2025
Department of Endocrinology, JSS Medical College, JSS Academy of Higher Education and Research, Mysore, India.
Background: Data on the carcinogenic potential of tirzepatide from randomized controlled trials (RCTs) are limited. Furthermore, no meta-analysis has included all relevant RCTs to assess the cancer risk associated with tirzepatide.
Methods: RCTs involving patients receiving tirzepatide in the intervention arm and either a placebo or any active comparator in the control arm were searched through electronic databases.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!